^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SCIB1

    i
    Other names: SCIB1, ImmunoBody melanoma vaccine, melanoma vaccine TRP2 gp100, SCIB 1, SCIB-1
    Associations

    News

    Trials
    Company:
    Scancell
    Drug class:
    gp100 inhibitor, TYRP2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors. (PubMed, Cancer Immunol Immunother)
    Here we show that SCIB1, a TRP-2 and gp100 directed ImmunoBody® DNA vaccine, generates a strong TRP-2 specific immune response, as demonstrated by the high number of TRP2-specific IFNγ spots produced and the detection of a significant number of pentamer positive T cells in the spleen of vaccinated mice...Time-to-death was significantly prolonged, and this correlated with increased CD4+ and CD8+ T cell infiltration in the tissue microenvironment (TME). However, in addition to PD-L1 and IDO, the GBM TME was found to contain a significant number of immunoregulatory T (Treg) cell-associated transcripts, and the presence of such cells is likely to significantly affect clinical outcome unless also tackled.
    Journal • Checkpoint inhibition • Checkpoint block
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule)
    |
    SCIB1
    5ms
    SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) (clinicaltrials.gov)
    P2, N=130, Recruiting, Scancell Ltd | N=87 --> 130
    Enrollment change • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • SCIB1
    over2years
    SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study) (clinicaltrials.gov)
    P2, N=87, Recruiting, Scancell Ltd | N=44 --> 87 | Trial completion date: Dec 2023 --> Jan 2026 | Trial primary completion date: Dec 2023 --> Jan 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • SCIB1
    3years
    A Phase 2, Multicenter, Open-Label Study of SCIB1 in Patients With Advanced Unresectable Melanoma Receiving Pembrolizumab (clinicaltrials.gov)
    P2, N=44, Recruiting, Scancell Ltd | N=25 --> 44
    Clinical • Enrollment change
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation
    |
    SCIB1